Logo image of LFST

LIFESTANCE HEALTH GROUP INC (LFST) Stock Fundamental Analysis

NASDAQ:LFST - Nasdaq - US53228F1012 - Common Stock - Currency: USD

5.26  -0.16 (-2.95%)

After market: 5.26 0 (0%)

Fundamental Rating

3

Taking everything into account, LFST scores 3 out of 10 in our fundamental rating. LFST was compared to 102 industry peers in the Health Care Providers & Services industry. While LFST seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, LFST is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year LFST has reported negative net income.
In the past year LFST had a positive cash flow from operations.
In the past 5 years LFST always reported negative net income.
In multiple years LFST reported negative operating cash flow during the last 5 years.
LFST Yearly Net Income VS EBIT VS OCF VS FCFLFST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

LFST has a Return On Assets (-1.68%) which is comparable to the rest of the industry.
LFST's Return On Equity of -2.43% is in line compared to the rest of the industry. LFST outperforms 50.98% of its industry peers.
Industry RankSector Rank
ROA -1.68%
ROE -2.43%
ROIC N/A
ROA(3y)-7.14%
ROA(5y)-11.82%
ROE(3y)-10.38%
ROE(5y)-16.71%
ROIC(3y)N/A
ROIC(5y)N/A
LFST Yearly ROA, ROE, ROICLFST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LFST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LFST Yearly Profit, Operating, Gross MarginsLFST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

4

2. Health

2.1 Basic Checks

LFST does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LFST has been increased compared to 1 year ago.
LFST has more shares outstanding than it did 5 years ago.
LFST has a worse debt/assets ratio than last year.
LFST Yearly Shares OutstandingLFST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M
LFST Yearly Total Debt VS Total AssetsLFST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

LFST has an Altman-Z score of 1.99. This is not the best score and indicates that LFST is in the grey zone with still only limited risk for bankruptcy at the moment.
LFST has a Altman-Z score (1.99) which is in line with its industry peers.
The Debt to FCF ratio of LFST is 2.80, which is a good value as it means it would take LFST, 2.80 years of fcf income to pay off all of its debts.
LFST has a Debt to FCF ratio of 2.80. This is in the better half of the industry: LFST outperforms 79.41% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that LFST is not too dependend on debt financing.
LFST's Debt to Equity ratio of 0.19 is fine compared to the rest of the industry. LFST outperforms 69.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 2.8
Altman-Z 1.99
ROIC/WACCN/A
WACC8.79%
LFST Yearly LT Debt VS Equity VS FCFLFST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 1.47 indicates that LFST should not have too much problems paying its short term obligations.
LFST has a Current ratio (1.47) which is comparable to the rest of the industry.
A Quick Ratio of 1.47 indicates that LFST should not have too much problems paying its short term obligations.
LFST's Quick ratio of 1.47 is in line compared to the rest of the industry. LFST outperforms 55.88% of its industry peers.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.47
LFST Yearly Current Assets VS Current LiabilitesLFST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

6

3. Growth

3.1 Past

LFST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.17%, which is quite impressive.
Looking at the last year, LFST shows a quite strong growth in Revenue. The Revenue has grown by 16.31% in the last year.
The Revenue has been growing by 42.55% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)79.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)16.31%
Revenue growth 3Y23.29%
Revenue growth 5Y42.55%
Sales Q2Q%10.83%

3.2 Future

LFST is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.71% yearly.
The Revenue is expected to grow by 12.39% on average over the next years. This is quite good.
EPS Next Y47.18%
EPS Next 2Y40.97%
EPS Next 3Y40.71%
EPS Next 5YN/A
Revenue Next Year14.17%
Revenue Next 2Y14.06%
Revenue Next 3Y14.2%
Revenue Next 5Y12.39%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LFST Yearly Revenue VS EstimatesLFST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B 2B
LFST Yearly EPS VS EstimatesLFST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

2

4. Valuation

4.1 Price/Earnings Ratio

LFST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LFST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LFST Price Earnings VS Forward Price EarningsLFST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K -1.5K -2K -2.5K

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, LFST is valued a bit more expensive than the industry average as 60.78% of the companies are valued more cheaply.
64.71% of the companies in the same industry are more expensive than LFST, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 20.09
EV/EBITDA 47.97
LFST Per share dataLFST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

LFST's earnings are expected to grow with 40.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.97%
EPS Next 3Y40.71%

0

5. Dividend

5.1 Amount

No dividends for LFST!.
Industry RankSector Rank
Dividend Yield N/A

LIFESTANCE HEALTH GROUP INC

NASDAQ:LFST (6/13/2025, 8:17:31 PM)

After market: 5.26 0 (0%)

5.26

-0.16 (-2.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-08 2025-08-08/bmo
Inst Owners36.53%
Inst Owner Change2.27%
Ins Owners2.9%
Ins Owner Change2.1%
Market Cap2.05B
Analysts81.33
Price Target8.89 (69.01%)
Short Float %7.17%
Short Ratio5.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)71.99%
Min EPS beat(2)43.98%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)56.42%
Min EPS beat(4)10.6%
Max EPS beat(4)100%
EPS beat(8)5
Avg EPS beat(8)9.87%
EPS beat(12)8
Avg EPS beat(12)7.21%
EPS beat(16)8
Avg EPS beat(16)-4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.11%
Min Revenue beat(2)-1.94%
Max Revenue beat(2)1.72%
Revenue beat(4)2
Avg Revenue beat(4)0.16%
Min Revenue beat(4)-1.94%
Max Revenue beat(4)1.72%
Revenue beat(8)4
Avg Revenue beat(8)0.56%
Revenue beat(12)6
Avg Revenue beat(12)0.23%
Revenue beat(16)8
Avg Revenue beat(16)0.04%
PT rev (1m)-1.35%
PT rev (3m)-3.17%
EPS NQ rev (1m)5.27%
EPS NQ rev (3m)11.76%
EPS NY rev (1m)0%
EPS NY rev (3m)32.36%
Revenue NQ rev (1m)-0.62%
Revenue NQ rev (3m)-1.85%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.59
P/FCF 20.09
P/OCF 16.25
P/B 1.4
P/tB N/A
EV/EBITDA 47.97
EPS(TTM)-0.1
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.26
FCFY4.98%
OCF(TTM)0.32
OCFY6.16%
SpS3.3
BVpS3.75
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.68%
ROE -2.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 7.93%
ROA(3y)-7.14%
ROA(5y)-11.82%
ROE(3y)-10.38%
ROE(5y)-16.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 2.8
Debt/EBITDA 5.68
Cap/Depr 38.82%
Cap/Sales 1.88%
Interest Coverage N/A
Cash Conversion 259.18%
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.47
Altman-Z 1.99
F-Score7
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)65.59%
Cap/Depr(5y)98.78%
Cap/Sales(3y)4.95%
Cap/Sales(5y)7.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y47.18%
EPS Next 2Y40.97%
EPS Next 3Y40.71%
EPS Next 5YN/A
Revenue 1Y (TTM)16.31%
Revenue growth 3Y23.29%
Revenue growth 5Y42.55%
Sales Q2Q%10.83%
Revenue Next Year14.17%
Revenue Next 2Y14.06%
Revenue Next 3Y14.2%
Revenue Next 5Y12.39%
EBIT growth 1Y92.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year429.54%
EBIT Next 3Y96.96%
EBIT Next 5YN/A
FCF growth 1Y682.28%
FCF growth 3YN/A
FCF growth 5Y98.76%
OCF growth 1Y202.74%
OCF growth 3Y124.79%
OCF growth 5Y44.39%